Women are underrepresented and gender-specific analysis is uncommon ...
Should pharmaceutical companies be allowed to discuss off-label use of their drugs?
Yes, it's a matter of First Amendment free speech rights.
No, unregulated promotion could expose patients to risky treatments.
Only to respond from unsolicited questions from healthcare professionals.